C Difficile

Ph.D. student Adrianne Gladden-Young uses her research to reduce racial health disparities and create pathways for scientists from underrepresented groups.

MicroRNA has shown the potential to more effectively and accurately identify C. difficile infections and manage it after diagnosis.

Clostridioides difficile is a Gram-positive opportunistic pathogen that results in 220,000 infections, 12,000 deaths, and upwards of $1 billion in medical costs in the United States each year. C. difficile is highly resistant to a variety of antibiotics, but we have a poor understanding of how C. di …

Clostridium difficile (CD) is known to be pathogenic when the balance of intestinal microbiota is disrupted by the administration of broad-spectrum antimicrobial agents. Therefore, CD enteritis ...

The presence of certain bacteria in the gastrointestinal tract may limit the effectiveness of antibiotic treatment for Clostridioides difficile.

yFMT could reshape the dysbiosis of gut microbiota and metabolites, maintain gut barrier integrity, and improve muscle mitochondrial dysfunction, eventually alleviating sarcopenia in aged rats. yFMT might be a new therapeutic strategy for age-related sarcopenia.

In patients receiving CPB, disturbances in gut mirobiota contributes to the development of PND possibly in relation with inflammatory response.

Summary Seres Therapeutics and Nestlé Health Science received FDA approval for VOWST, a drug to prevent recurrent C. difficile infection, triggering a $125M payment from Nestlé to Seres.Seres reported a Q1 2023 net loss of $71.2M, up from a $56.6M loss in Q1 2022, with increased expenses due to VOWST development and manufacturing costs.The company ...

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been busy this year in Washington DC with an FDA event and their Summit and Advocacy Day with lawmakers.

Here is a brief report of 5 cases of the use of fecal microbiota, live-jslm (Rebyota) in the management of recurrent Clostridioides difficile infection.

Hamilton Health Sciences’ (HHS) McMaster Children’s Hospital (MCH) has opened Canada’s first pediatric stool bank. The healthy stool samples are used to create a treatment for the recurring gut infection Clostridium difficile, or C. diff, in children when antibiotics haven’t worked. This treatment has become a common procedure in adults but MCH is on the leading edge of using it for children.

Overuse of antibiotics increases adverse side effects, including C diff

This is the first epidemiological study associating Cdiff with an increased risk for colon cancer. Future studies should further evaluate this relationship.

Diagnostic stewardship decreases unnecessary antibiotic use in a way that is different from and complementary to antibiotic stewardship. Further studies are needed to quantify the full impact on antibiotic use and resistance. Future considerations should be to institutionalize diagnostic stewardship …

The largest safety evaluation of any microbiota-based live biotherapeutic reveals data for the first approved microbiome therapy for C. diff.

A simplified approach using prior healthcare exposure and receipt of prior antibiotics known to increase CDI risk identified patients at risk for MDRO gut microbiome colonization as effectively as individual patient/antibiotic risk modeling.

VGH and UBC Hospital Foundation, Vancouver Coastal Health‘s primary philanthropic partner that raises funds for specialized adult health services and research for all British Columbians, on Wednesday announced that the Canines for Care team welcomed two new adult dogs, Arti and Anton, into their program. “Arti and Anton passed their stringent certification testing after thousands […]

Administrating the donor's transplant to the small intestine had a higher response and results in long-term colonization of beneficial bacteria than administrating it to the large intestine.

Learn about the best probiotics for IBS, Diverticulitis, Diverticulosis, Ulcerative Colitis, and Clostridium difficile infection.

These data support the development of omilancor as a novel host-targeted, antimicrobial-free immunoregulatory therapeutic for the treatment of IBD patients with C. difficile-associated disease and pathology with the potential to address the unmet clinical needs of ulcerative colitis and Crohn's dise …

Severe outbreaks and deaths have been linked to the emergence and global spread of fluoroquinolone-resistant Clostridioides difficile over the past two decades. At the same time, metronidazole, a nitro-containing antibiotic, has shown decreasing clinical efficacy in treating C. difficile infection ( …

Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes of patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating g …

The gut microbiota and bile acid metabolism are key determinants of the response of inflammatory bowel disease to biologic therapy. However, the molecular mechanisms underlying the interactions between the response to anti-α4β7-integrin therapy and the gut microbiota and bile acid metabolism remain …

Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as the primary therapy for initial CDI episodes and suggest alternative approaches for recurrent episodes, including fecal mi …

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been busy this year in Washington DC with an FDA event and their Summit and Advocacy Day with lawmakers.

Infections contracted from catheters, ventilators and central lines grew in Oregon during the pandemic

Misclassification of iClostridioides difficile/i colonization as hospital-onset iC. difficile/i infection (HO-CDI) can lead to unnecessary treatment of patients and substantial financial penalties for hospitals. We successfully implemented mandatory iC. difficile/i PCR testing approval a …

Diagnostic stewardship decreases unnecessary antibiotic use in a way that is different from and complementary to antibiotic stewardship. Further studies are needed to quantify the full impact on antibiotic use and resistance. Future considerations should be to institutionalize diagnostic stewardship …

Inappropriate dental antibiotic prescriptions to prevent infective endocarditis in the United States results in ∼$31 million in excess costs to the healthcare system and patients. This includes out-of-pocket costs ($20.5 million), drug costs ($2.69 million) and adverse event costs (eg, Clostridio …

Misclassification of Clostridioides difficile colonization as hospital-onset C. difficile infection (HO-CDI) can lead to unnecessary treatment of patients and substantial financial penalties for hospitals. We successfully implemented mandatory C. difficile PCR testing approval a …